DMD and IL1RAPL1: Two large adjacent genes localized within a common fragile site (FRAXC) have reduced expression in cultured brain tumors

Cytogenetic and Genome Research

Volumn 119, Issue 3-4, 2007, Pages 196-203

  McAvoy, S ^a   Ganapathiraju, S ^a   Perez, D S ^a   James, C D ^b   Smith, D I ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN LIKE 1; RAD51 LIKE 1 PROTEIN; RAD51 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DCC GENE; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION; GENE LOCATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WWOX GENE; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHROMOSOME FRAGILE SITES; DNA-BINDING PROTEINS; DOWN-REGULATION; DYSTROPHIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; MALE; MIDDLE AGED; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 39049149919     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112061     Document Type: Article

References (57)

1. Aqeilan RI, Kuroki T, Pekarsky Y, Albagha O, Trapasso F, et al: Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 10:3053-3058 (2004).
2. Arlt MF, Miller DE, Beer DG, Glover TW: Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosomes Cancer 33:82-92 (2002).
3. Arlt MF, Casper AM, Glover TW: Common fragile sites. Cytogenet Genome Res 100:92-100 (2003).
4. Arlt MF, Durkin SG, Ragland RL, Glover TW: Common fragile sites as targets for chromosome rearrangements. DNA Repair (Amst) 5:1126-1135 (2006).
5. Arun B, Kilic G, Yen C, Foster B, Yardley DA, et al: Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers Prev 14:1681-1685 (2005).
6. Baumann P, Benson FE, West SC: Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 87:757-766 (1996).
7. Becker NA, Thorland EC, Denison SR, Phillips LA, Smith DI: Evidence that instability within the FRA3B region extends four megabases. Oncogene 21:8713-8722 (2002).
8. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM: WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.2-24.1, a region frequently affected in breast cancer. Cancer Res 60:2140-2145 (2000).
9. Boukhtouche F, Vodjdani G, Jarvis CL, Bakouche J, Staels B, et al: Human retinoic acid receptor-related orphan receptor alpha1 overexpression protects neurons against oxidative stress-induced apoptosis. J Neurochem 96:1778-1789 (2006).
10. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, et al: Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 100:5956-5961 (2003).
11. Denison SF, Callahan G, Becker NA, Phillips LA, Smith DI: Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer 38:40-52 (2003).
12. Deorah S, Lynch CF, Bibenaller ZA, Ryken TC: Trends in brain cancer incidence and survival in the United States: Surveillance, epidemiology, and end results program. 1973 to 2001. Neurosurg Focus 20:E1 (2006).
13. Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili Z, et al: Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 57:504-512 (1997).
14. Dumon KR, Ishii H, Fong LY, Zanesi N, Pidanza V, et al: FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA 98:3346-3351 (2001).
15. Dussaulat I, Fawcett D, Matthyssen A, Bader JA, Giguere V: Orphan nuclear receptor ROR alpha-deficient mice display the cerebellar defects of staggerer. Mech Dev 70:147-153 (1990).
16. Engelman JA, Zhang XL, Lisanti MP: Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 436:403-410 (1998).
17. Fabbri M, Iliopoulos D, Traposso F, Aqeilan RI, Cimmino A, et al: WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci USA 102:15611-15616 (2005).
18. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, et al: Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247:49-56 (1990).
19. Ferber MJ, Thorland EC, Brink AA, Rapp AK, Phillips LA, et al: Preferential integration of human papillomavirus type 18 near the c-Myc locus in cervical carcinoma. Oncogene 22:7233-7242 (2003).
20. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, et al: Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:164-176 (2005).
21. Ginestier C, Bardou VJ, Popvici C, Charafe-Jauffret E, Bertucci F, et al: Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. Int J Cancer 107:854-862 (2003).
22. Glover TW, Berger C, Coyle J, Echo B: DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 67:136-145 (1984).
23. Gotte K, Hadaczek P, Coy JF, Wirtz HW, Riedel F, et al: Fhit expression is absent or reduced in a subset of primary head and neck cancer. Anticancer Res 20:1057-1060 (2000).
24. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, et al: The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 100:1605-1614 (2004).
25. Hadaczek P, Siprashvili Z, Markiewski M, Domagala W, Druck T, et al: Absence of reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res 58:2946-2951 (1998).
26. Helmrich A, Stout-Weider K, Matthaei A, Hermann K, Heiden T, Schrock E: Identification of the human/mouse syntenic common fragile site FRA7K/Fra12C 1-relation of FRA7K and other human common fragile sites on chromosome 7 to evolutionary breakpoints. Int J Cancer 120:48-54 (2007).
27. Hormozian F, Schmitt JG, Sagulenko E, Schwab M, Savelyeva L: FRA1E common fragile site breaks map within a 370 kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD). Cancer Lett 246:82-91 (2007).
28. Iliopoulos D, Guler G, Han SY, Druck T, Ottey M, et al: Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett 232:27-36 (2006).
29. Jin H, Gardner RJ, Viswesvaraiah R, Muntoni F, Roberts RG: Two novel members of the interleukin-1 receptor gene family, one deleted in Xp22.1-Xp21.3 mental retardation. Eur J Hum Genet 8:87-94 (2000).
30. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, et al: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608 (1998).
31. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM: Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:509-517 (1987).
32. Krummel KA, Roberts LR, Kawakami M, Glover TW, Smith DI: The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics 69:37-46 (2000).
33. Lalouette A, Guenet JL, Vriz S: Hotfoot mouse mutations affect the delta 2 glutamate receptor gene and are allelic to lurcher. Genomics 50:9-13 (1998).
34. McAvoy S. Ganapathiraju SC, Ducharme-Smith AL, Pritchett JR, Kosari F, et al: Non-random inactivation of large common fragile site genes in different cancers. Cytogenet Genome Res 118:260-269 (2007).
35. Mishmar D, Rahat A, Scherer SW, Nyakatura G, Hinzmann B, et al: Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc Natl Acad Sci USA 95:2311-2319 (1998).
36. Paige AJ, Taylor KJ, Taylor C, Hillier SG, Farrington S, et al: WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 98:11417-11422 (2001).
37. Park SW, Ludes-Meyers J, Zimonjic DB, Durkin ME, Popescu NC, Aldaz CM: Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer 91:753-759 (2004).
38. Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R, Bednarek AK: WWOX - the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol 32:153-157 (2006).
39. Ramos D, Aldaz CM: WWOX, a chromosomal fragile site gene and its role in cancer. Adv Exp Med Biol 587:149-159 (2006).
40. Rozier L, El-Achkar E, Apiou F, Debatisse M: Characterization of a conserved aphidicolin-sensitive common fragile site at human 4q22 and mouse 6C1: possible association with an inherited disease and cancer. Oncogene 23:6872-6880 (2004).
41. Savelyeva L, Sagulenko E, Schmitt JG, Schwab M: The neurobeachin gene spans the common fragile site FRA13A. Hum Genet 118:551-558 (2006).
42. Sekiguchi M: The role of dystrophin in the central nervous system: a mini review. Acta Myol 24:93-97 (2005).
43. Shinohara A, Ogawa H, Matsuda Y, Ushio N, Ikeo K, Ogawa T: Cloning of human, mouse and fission yeast recombination genes homolgous to RAD51 and recA. Nat Genet 4:239-243 (1993).
44. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, et al: Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 94:13771-13776 (1997).
45. Smith DI, Huang H, Wang L: Common fragile sites and cancer (review). Int J Oncol 12:187-196 (1998).
46. Smith DI, Zhu Y, McAvoy S, Kuhn R: Common fragile sites, extremely large genes, neural development and cancer. Cancer Lett 232:48-57 (2006).
47. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, et al: The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85:17-26 (1996).
48. Sutherland GR: Rare fragile sites. Cytogenet Genome Res 100:77-84 (2003).
49. Sutherland GR, Baker E: The clinical significance of fragile sites on human chromosomes. Clin Genet 58:157-161 (2000).
50. Sutherland GR, Richards RI: The molecular basis of fragile sites in human chromosomes. Curr Opin Genet Dev 5:323-327 (1995a).
51. Sutherland GR, Richards RI: Simple tandem DNA repeats and human genetic disease. Proc Natl Acad Sci USA 92:3636-3641 (1995b).
52. Tabolacci E, Pomponi MG, Pietrobono R, Terracciano A, Chiurazzi P, Neri G: A truncating mutation in the IL1RAPL1 gene is responsible for X-linked mental retardation in the MRX21 family. Am J Med Genet A 140:482-487 (2006).
53. Verkerk AJ, Mathews CA, Hoose M, Eussen BH, Heutink P, Oostra BA: Tourette Syndrome Association International Consortium for Genetics: CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. Genomics 82:1-9 (2003).
54. Wheway JM, Yau SC, Nihalani V, Ellis D, Irving M, et al: A complex deletion-inversion event results in a chimeric IL1RAPL1-dystrophin transcript and a contiguous gene deletion syndrome. J Med Genet 40:127-131 (2003).
55. Zhang YH, Huang BL, Niakan KK, McCabe LL, McCabe ER, Dipple KM: IL1RAPL1 is associated with mental retardation in patients with complex glycerol kinase deficiency who have deletions extending telomeric of DAX1. Hum Mutat 24:273 (2004).
56. Zhao P, Lam AK, Lu YL, Zhong M, Chen LH, Pu XL: Aberrant FHIT protein expression in classical Hodgkin's lymphoma: a potential marker. Pathology 38:399-402 (2006).
57. Zhu Y, McAvoy S, Kuhn R, Smith DI: RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene 25:2901-2908 (2006).